← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Syntrix Biosystems, Inc.
Auburn, WA
$37,670,752
Total funding
25
Grants
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$37,670,752 · 25
By mechanism
R44$29,053,079 · 13
R43$6,948,886 · 11
U44$1,668,787 · 1
Investigators at Syntrix Biosystems, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD$1,887,898
R44 · FY2014 · HL
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients$1,575,472
R44 · FY2020 · HL
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients$1,424,426
R44 · FY2019 · HL
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects$1,204,753
R44 · FY2020 · DA
Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD$1,147,002
R44 · FY2012 · HL
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$1,125,311
R44 · FY2018 · CA
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine$997,596
R44 · FY2017 · DA
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine$990,418
R44 · FY2016 · DA
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine$977,024
R44 · FY2018 · DA
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers$933,466
R44 · FY2013 · DA
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)$903,852
R44 · FY2025 · CA
Phase II clinical evaluation of Omnitram in neuropathic pain$842,819
R44 · FY2016 · DA
Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD$811,424
R44 · FY2011 · HL
Aminotrexate A Novel Strategy to Replace Methotrexate in Psoriasis$791,030
R43 · FY2006 · AI
Instrumentation For High-Resolution Analysis of Cancer$750,754
R44 · FY2004 · CA
Instrumentation For High-Resolution Analysis of Cancer$746,571
R44 · FY2005 · CA
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)$745,050
R44 · FY2024 · CA
Artificial Antibody Mimetics$725,229
R44 · FY2005 · CA
Artificial Antibody Mimetics$714,186
R44 · FY2004 · CA
Bronchopulmonary Dysplasia Drug Therapy$711,818
R44 · FY2005 · HL